Key regions: China, Europe, Australia, United States, Germany
The Other Pharmaceuticals market in Poland has been experiencing steady growth in recent years.
Customer preferences: Poland has a rapidly aging population, which has increased the demand for pharmaceutical products. Additionally, the country's growing middle class has more disposable income to spend on healthcare, including pharmaceuticals. Customers are seeking out high-quality, affordable medications to treat a variety of ailments, and are increasingly turning to generic drugs as a cost-effective alternative to brand-name options.
Trends in the market: One of the key trends in the Other Pharmaceuticals market in Poland is the increasing popularity of over-the-counter (OTC) medications. As more consumers seek out self-care options for minor ailments, OTC drugs have become a more attractive option. Additionally, the market is seeing increased competition from international pharmaceutical companies, which are entering the Polish market and introducing new products.
Local special circumstances: Poland's healthcare system is undergoing significant changes, which are impacting the Other Pharmaceuticals market. The government has introduced a number of reforms aimed at improving the efficiency and effectiveness of the healthcare system, including changes to reimbursement policies and the introduction of a new electronic prescription system. These changes are creating new opportunities for pharmaceutical companies to expand their market share, but are also creating challenges as companies navigate new regulations and reimbursement policies.
Underlying macroeconomic factors: Poland's strong economic growth in recent years has been a major driver of the Other Pharmaceuticals market. The country's GDP has been growing steadily, and the government has made significant investments in healthcare infrastructure. Additionally, Poland's membership in the European Union has created new opportunities for pharmaceutical companies to expand their reach across the region. However, the market also faces challenges related to regulatory compliance and intellectual property protection. As the market continues to evolve, companies will need to stay abreast of these trends and adapt their strategies accordingly.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
